Drugs /

craniospinal irradiation

Back to Drugs List

Overview

NCI Definition [1]:
The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.

Clinical Trials

View Clinical Trials for craniospinal irradiation

Craniospinal irradiation has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating craniospinal irradiation, 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).

APC Loss, APC Mutation (germline), and CTNNB1 Exon 3 Mutation (somatic) are the most frequent biomarker inclusion criteria for craniospinal irradiation clinical trials.

Medulloblastoma, intracranial primitive neuroectodermal neoplasm, and small cell lung carcinoma are the most common diseases being investigated in craniospinal irradiation clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Craniospinal Irradiation
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating craniospinal irradiation and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
craniospinal irradiation
NCIT ID [1]:
C116437

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.